AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02754505 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early rehabilitation
Description: The early rehabilitation program consisted of a coordinated exercise therapy and neuromuscular electrical stimulation, for two hours and five days a week until discharge from the acute hospital. Exercise therapy included strength training (three days/week, one to three sets of 12-15 repetitions, 8-10 exercises involving the major muscle groups: thighs, calves, buttocks, trunk, shoulder girdle), aerobic exercise (large muscle activities five days/week, 10-30 min/session, 50-80% maximal heart rate) and active breathing techniques. For neuromuscular electrical stimulation we applied Compex-P© devices producing biphasic symmetric impulses with a frequency of 50 Hz and a pulse width of 0.35 ms (stimulus regime: 8 s on/24 s off) five days/week, 30 min/session involving the anterior thighs and buttocks.
Study NCT02754505 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: exercise therapy, respiratory therapy, neuromuscular electrical stimulation (as described above).
Study NCT06537635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cubii seated compact elliptical trainer
Description: The Cubii® Pro is an under-desk seated elliptical trainer. This device provides 8 levels of resistance and documents the total number of strides, distance covered in miles, and calories expended during an activity session.
Study NCT01702766 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animalis subsp. lactis
Study NCT00981864 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Boost RT
Description: Patient will receive radiation to the tumour bed concurrently with whole breast radiation instead of receiving this treatment sequentially, that is, whole breast RT first then followed by RT directly to the tumour bed.
Study NCT02261272 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: passive patient education/sleep hygiene
Study NCT04245397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)
Study NCT03454061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: Physical education program (PEP) of 16-week length
Study NCT01982617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Study NCT01982617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Study NCT02818205 — intervention group
Intervention type: OTHER
Intervention: Sensory Challenge Protocol
Description: Measurement of electrodermal activity in response to sensation
Study NCT04245397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is a hypomethylating agent.
Study NCT01882634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound (Trademark:VScan; Manufacturer:General Electric)
Description: Standardized measurements were made and aorta will be visualized in a minimum of three hard copy images: upper transverse projection abdominal aorta at the level of epigastrium (celiac trunk) lower transverse section for distal view of aorta (pre-bifurcation), and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm)
Study NCT00822510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Interpersonal Counseling
Description: Telephone delivered 8 week education and counseling intervention based on interpersonal psychotherapy.
Study NCT00712712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Intravenous administration of paracetamol (4 g / 24h) and patient-controlled analgesia (PCA).
Study NCT00712712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: Patient-controlled analgesia (PCA), allowing morphine consumption to be titrated to the patient's needs and thus allowing morphine doses to be adapted to an increase in pain in the patient's post-operative period or a rapid analgesic effect of radiofrequency.
Study NCT00712712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Pain notebook will allow the patient to describe the pain specific to the metastasis concerned, containing information on :~* The intensity of the minimum, average and maximum pain of the last 24 months. hours as well as the intensity of the pain of the moment according to a scale 11-point digital,~* the background morphine analgesic treatment during the last 24 hours,~* the morphine analgesic treatment taken during painful attacks,~* the possible undesirable effects of morphine treatment.~* the morphinic, non-morphinic and co-antalgic treatment is noted, as well as that the total dose of oral morphine or oral morphine equivalent
Study NCT00712712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Patients' quality of life will be assessed using the quality of life questionnaire EORTC QLQ-C30 at inclusion in the study and at 8 weeks after radiofrequency. ablation.
Study NCT00712712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Recent technique of thermal destruction of tumors.~This technique consists of inserting an electrode needle into the tumour under X-ray or ultrasound guidance or intraoperatively under laparoscopy for example. This needle carries a current or a light wave depending on the characteristics of the generator to which it is connected (radiofrequency, laser).~Radio frequencies are radiation non-ionising electromagnets. In this context of tissue ablathermia wavelengths ranging from 400kHz to 500kHz.
Study NCT01332669 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: DebDox TACE
Description: HCC patients will receive chemoembolization (TACE) using DC beads containing Doxorubicin. The objective is to give 2 vials of DC Bead (2ml per vial) loaded with 70-75mg of Doxorubicin per vial (Each vial contain 2ml of DC Bead, thus doxorubicin concentration will be of 35-37.5mg per ml of DC Beads)
Study NCT01332669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DebDox TACE
Description: HCC patients will receive chemoembolization (TACE) using DC beads containing Doxorubicin. The objective is to give 2 vials of DC Bead (2ml per vial) loaded with 70-75mg of Doxorubicin per vial (Each vial contain 2ml of DC Bead, thus doxorubicin concentration will be of 35-37.5mg per ml of DC Beads)
Study NCT00333827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: optimal therapy for cardiaca failure
Description: optimal therapy for cardiaca failure
Study NCT00333827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cell
Description: stem cell
Study NCT04207606 — intervention group
Intervention type: BEHAVIORAL
Intervention: Post Epidural Steroid Injection Follow-up
Description: All enrolled patients will undergo epidural steroid injection with fluoroscopy per the Spine Intervention Society guidelines as part of their normal care. Patients will then be contacted for survey responses every 3 days for a maximum of 23 days, to assess pain intensity and change.
Study NCT04390919 — intervention group
Intervention type: OTHER
Intervention: elevated monocyte count
Description: The monocyte count at admission was higher than 0.445×10\*9 cells/L
Study NCT01114035 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood samples and skin biopsies
Description: to detect mutations
Study NCT01114035 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Skin biopsies
Description: to detect mutations
Study NCT02689154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: W8Loss2Go
Description: The participants will proceed through all parts of the app program (problem food withdrawal, snacking control and withdrawal from excessive portions) and receive weekly phone calls from the study coordinator, who will be monitoring app usage and providing motivation. Subjects will return to the EMPOWER clinic for a three month weight check and face-to-face meeting with their mentor. After the study period, participants will again complete the EBQ, and be offered continued enrollment in the EMPOWER clinic or continued home use of the mHealth technology.
Study NCT04656821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Rx
Description: Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed
Study NCT04656821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Block
Description: Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
Study NCT00822510 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone delivered education only
Description: Telephone delivered 8 week educational intervention on prostate cancer health, side effects, physical activity, diet, smoking cessation
Study NCT04656821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Paravertebral Block
Description: Patients of this group will receive 25 mg bupivacaine 0.5% , plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at desired level under ultrasonography
Study NCT00086619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: synthetic hPTH 1-34
Description: Either daily treatment with self-injected hPTH 1-34 or ascending dose treatment at 6-month intervals of hPTH 1-34
Study NCT00532454 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen
Description: tamoxifen 20mg, PO, QD until disease progression
Study NCT02290756 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Program
Description: The parenting program is an early childhood stimulation program aimed at newborns from their neonatal period till infancy. The implementation of the parenting program will be conducted through the link workers and parents of the newborns.
Study NCT02290756 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low cost evidence based toolkit
Description: The aim of providing the toolkit is to ensure that all pregnant women in the project are provided the requisite care needed from the antenatal period till delivery to limit complications and insults (both mother and especially the neonate) that can occur during pregnancy, delivery and post partum in both the mother and child. The contents of the toolkit will include:~1. Clean delivery kit, aspiration bulb, bag and mask, Chlorhexidine, Misoprostol, Nutritional supplements (Iron and folic acid, awareness about breastfeeding) and IEC materials~2. Trainings for Birth Attendants and Link workers on aspiration and hypothermia management techniques, use of bag and mask APGAR (also to parents), cord care, basic pregnancy and newborn care information
Study NCT02329496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Valve and LOTUS Edge Valve System
Description: Transcatheter aortic valve replacement (TAVR) with the Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System, with either the Lotus Introducer or iSleeve Introducer Sets
Study NCT01986400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Peer-to-Peer Support Mentoring
Description: The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
Study NCT02806635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OurRelationship
Study NCT02806635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREP Online
Study NCT02773446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer
Description: ETEC Bacteria
Study NCT03001856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oblique Intradermal Suture
Study NCT03001856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intradermal Suture
Study NCT03510013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1-1-8 wash-in
Description: wash-in phase during start of low flow anesthesia
Study NCT03510013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Drug used for wash-in protocol
Study NCT01066039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Bisoprolol tablet will be administered orally at dose of 5 milligram (mg) once daily for 24 weeks. If the blood pressure is not less than 130/80 millimeter of mercury (mmHg) during the first 8 weeks of treatment (up-titration), then the dose will be adjusted to 10 mg daily. In cases of hypotensive effect, symptomatic bradycardia or arrhythmia, the daily dose will be reduced to 2.5 mg.
Study NCT01902524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl-TTS
Description: All of the participants will receive the study drug at least once transdermally, administration dosage starts at 12.5 microgram/hour.
Study NCT02290756 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low cost evidence based toolkit
Description: The aim of providing the toolkit is to ensure that all pregnant women in the project are provided the requisite care needed from the antenatal period till delivery to limit complications and insults (both mother and especially the neonate) that can occur during pregnancy, delivery and post partum in both the mother and child. The contents of the toolkit will include:~1. Clean delivery kit, aspiration bulb, bag and mask, Chlorhexidine, Misoprostol, Nutritional supplements (Iron and folic acid, awareness about breastfeeding) and IEC materials~2. Trainings for Birth Attendants and Link workers on aspiration and hypothermia management techniques, use of bag and mask APGAR (also to parents), cord care, basic pregnancy and newborn care information
Study NCT01772810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human spinal cord stem cells.
Description: Human spinal cord stem cell implantation in paralysis patients due to a spinal cord injury.
Study NCT02996968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-removal
Description: Self-discontinuation of a transurethral catheter
Study NCT01323400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib is administered orally at 800 mg/day (one dose every morning). A dose modification is possible in case of documented toxicity, according to specific algorithms.
Study NCT01323400 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best supportive care
Description: Best supportive care according to the investigator's judgment (chemotherapy, immunotherapy, hormone therapy are not allowed).~Non-targeted radiation therapy is tolerated, as antalgic strategy. Surgery is tolerated in case of emergency.
Study NCT01323400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Best supportive care according to the investigator's judgment (chemotherapy, immunotherapy, hormone therapy are not allowed).~Non-targeted radiation therapy is tolerated, as antalgic strategy. Surgery is tolerated in case of emergency.
Study NCT03141931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg
Study NCT03141931 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)
Study NCT02426125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT02426125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Administered IV
Study NCT02426125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered IV
Study NCT02426125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT04029584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin IV
Description: A 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline will be used to inhibit hepatic OATP1B1 transporters.
Study NCT04029584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifadin 300Mg Capsule
Description: Rifadin 600mg by mouth as two 300mg rifadin capsules
Study NCT00981409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium
Description: The dose of Fondaparinux will be determined based on a subject's body weight (\<50 kg, 5 mg; 50 to 100 kg, 7.5 mg; >100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
Study NCT04029584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 MG
Description: one oral dose of fluvastatin (Lescol ) 20mg capsule
Study NCT02992353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three-port pulmonary resection surgery
Description: Three-port pulmonary resection surgery
Study NCT02992353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-port or two-port surgery
Description: Single-port or two-port pulmonary resection surgery
Study NCT00639301 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The survey will be administered by mail or telephone interview, based upon the participant preference. The survey has been adapted from the 2008 questionnaire being administered through the CCSS (11); it has been supplemented with questions addressing areas of interest specific to the retinoblastoma survivor population (eg, validated instruments that assess visual impairment).
Study NCT03192449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole.
Description: Single dose 400mg orally
Study NCT02861690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Paclitaxel
Description: Patients received Liposomal Paclitaxel 175mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
Study NCT02861690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Patients received Nedaplatin80mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
Study NCT02564198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT02451657 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention was administered in this study
Study NCT00208429 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pinnacle Acetabular System
Study NCT01629628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneous adalimumab injections, loading dose of 160 mg and 80 mg on 0 and 2 weeks and maintenance of 40 mg every other week for the duration of the study.
Study NCT01629628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 Mercaptopurine
Description: 6MP will be administered orally starting at a dose of 6MP of 50mg/day with escalating doses every 1-2 weeks as tolerated, to a target dose of 1-1.5 mg/kg.~--------------------------------------------------------------------------------
Study NCT00966992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT03658785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL
Description: On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine)
Study NCT03658785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: IL-2 125,000 IU/kg/day IV (based on total body weight) beginning within 24 hours of cell infusion and continuing for up to 2 weeks
Study NCT03658785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
Study NCT00981409 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: unfractionated heparin (UFH)
Description: UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
Study NCT01898858 — intervention group
Intervention type: DEVICE
Intervention: Hypercapnia inhalation (Altitrainer NP 190)
Description: Hypercapnia inhalation using an Altitrainer NP 190
Study NCT01898858 — intervention group
Intervention type: DEVICE
Intervention: Hypoxia and hypercapnia (Altitrainer NP 190)
Description: Hypoxia and hypercapnia inhalation using an Altitrainer NP 190
Study NCT01898858 — intervention group
Intervention type: DEVICE
Intervention: Hypoxia inhalation (Altitrainer NP 190)
Description: Hypoxia inhalation using an Altitrainer NP 190